Winona LegitScript and Accreditation Status: Is Winona Legit?

What Is Winona and How Does Its Telehealth Model Work?

Winona is a direct-to-consumer telehealth platform focused exclusively on menopause care and hormone replacement therapy (HRT). Patients complete an online intake questionnaire, a licensed physician reviews responses asynchronously, and a prescription is issued if appropriate. Medication is then dispensed through a compounding pharmacy and shipped to the patient's home.

The asynchronous prescribing model

Winona does not require a synchronous video visit in most states. Prescriptions are generated after a physician reviews the patient's health history form. This model is legal in many U.S. Jurisdictions under telehealth flexibilities that expanded after 2020, but it differs from the standard of care described in the Menopause Society's 2023 position statement, which calls for individualized clinical evaluation before initiating systemic HRT. The Menopause Society (formerly NAMS) states: "Hormone therapy decisions should be individualized and based on a comprehensive assessment of a woman's symptoms, risk factors, and preferences."

Asynchronous prescribing introduces a specific limitation: the physician cannot ask real-time follow-up questions. For HRT candidates who have a personal history of estrogen-sensitive cancers, clotting disorders, or uncontrolled cardiovascular disease, this gap carries real clinical weight.

Compounded versus FDA-approved hormones

A majority of Winona's prescriptions involve compounded bioidentical hormones rather than FDA-approved brand products like Vivelle-Dot (estradiol patch) or Prometrium (micronized progesterone). Compounded hormones are not FDA-approved. The FDA has noted that compounded drugs are not evaluated for safety, efficacy, or quality in the same way as approved drugs, and this distinction matters when assessing any telehealth company's regulatory standing.

Does Winona Have LegitScript Certification?

Winona does not appear in LegitScript's publicly searchable database of certified online pharmacies or telehealth providers as of January 2025. This is a factual gap worth examining carefully.

What LegitScript certification means

LegitScript is a third-party verification organization that reviews online pharmacies and telehealth platforms for compliance with applicable laws, including DEA scheduling, state pharmacy licensing, and prescribing standards. Google, Bing, and Meta use LegitScript certification as a prerequisite for running pharmaceutical advertising. A company can operate legally without LegitScript certification, but the absence of certification removes one independent layer of external review.

LegitScript's published standards require, among other criteria, that certified pharmacies dispense only pursuant to valid prescriptions, operate with appropriate state licenses, and disclose all dispensing pharmacy locations. The absence of Winona from the certified list does not prove a violation, but it does mean patients cannot rely on LegitScript as a trust signal for this platform.

Why this matters for compounding pharmacies specifically

Compounding pharmacies that operate under FDA 503A rules (patient-specific prescriptions) are not subject to the same Current Good Manufacturing Practice (cGMP) standards as commercial drug manufacturers. The FDA's guidance on 503A compounders makes clear that these facilities are primarily regulated at the state board of pharmacy level. Patients should confirm that Winona's dispensing pharmacy holds an active license in the patient's state of residence before accepting a shipment.

The HealthRX editorial team developed the following three-checkpoint verification framework for evaluating any HRT telehealth platform's legitimacy:

1. Licensing check. Confirm the platform's dispensing pharmacy holds an active license in your state via your state board of pharmacy's online lookup tool.
2. Prescriber check. Verify the signing physician's license on your state medical board's public database.
3. Formulation check. Ask whether the prescribed hormone is FDA-approved or compounded, and request the Certificate of Analysis (COA) from the dispensing pharmacy.

Winona Complaints: What the BBB and Consumer Records Show

Winona is not accredited by the Better Business Bureau. Consumer complaint patterns documented on the BBB website and on Trustpilot (as of early 2025) include billing disputes, difficulty canceling subscriptions, delays in receiving medication, and concerns about the thoroughness of the intake evaluation.

Billing and subscription complaints

The most common category of consumer complaints involves recurring charges after patients believed they had canceled. This pattern is not unique to Winona, and it appears across multiple cash-pay telehealth companies. The FTC's Negative Option Rule amendments (2023) require that cancellation be as easy as the original sign-up. Patients who believe they were charged after cancellation have the option to dispute the charge with their credit card issuer and file a complaint with the FTC at ReportFraud.ftc.gov.

Concerns about clinical thoroughness

Some reviewers reported receiving prescriptions without what they considered adequate follow-up on their stated risk factors. This is a structural limitation of asynchronous telehealth rather than a Winona-specific failing, but it surfaces disproportionately in negative reviews. The 2022 ACOG Clinical Consensus on Hormone Therapy recommends that prescribers document a patient's personal and family history of hormone-sensitive malignancy before initiating systemic estrogen. Whether asynchronous intake forms adequately capture this information is a legitimate clinical question.

Positive reviews and what they reflect

Positive reviews consistently cite convenience, cost savings compared to in-person gynecology visits, and symptom improvement. For patients in areas with limited access to menopause-specialist care, the convenience argument is real. A 2022 analysis in Menopause journal found that fewer than 7% of ob-gyn residents felt adequately trained to manage menopause, suggesting an access gap that direct-to-consumer platforms do try to fill.

FDA Oversight of Winona's Products

Winona prescribes both FDA-approved hormones (in some cases) and compounded formulations. The two categories carry different regulatory profiles.

FDA-approved HRT options

FDA-approved estradiol and progesterone products have passed efficacy and safety review. For systemic menopause symptoms, the FDA approves estradiol in patch, gel, spray, and oral forms, and oral micronized progesterone (Prometrium 100 mg, 200 mg) for endometrial protection. When Winona prescribes these products through a licensed pharmacy, the product's quality is subject to standard pharmaceutical manufacturing requirements.

Compounded "bioidentical" hormones

The term "bioidentical" is not an FDA regulatory category. The FDA has explicitly stated that it has not approved any drug as "bioidentical," and that compounded formulations using this term are not evaluated for safety or efficacy before reaching patients. Winona markets hormone formulations using bioidentical language, which is common in the industry but does not confer regulatory approval.

Compounded testosterone for women is a particular area of regulatory ambiguity. No FDA-approved testosterone product is labeled for use in women. Off-label prescribing is legal for physicians, but compounded testosterone formulations for women exist entirely outside the FDA approval pathway. The Endocrine Society's 2014 guideline on testosterone therapy in women (Wierman et al.) noted that evidence for benefit is limited to sexual dysfunction in postmenopausal women and that data on long-term safety are insufficient for most other indications.

State Licensing and Prescriber Credentials

Winona's physicians must hold active licenses in each state where they issue prescriptions. Patients can verify this independently.

How to verify your prescribing physician

Every state maintains a public database of licensed physicians. The Federation of State Medical Boards (FSMB) provides a DocInfo lookup tool that aggregates license status and disciplinary actions across states. Before filling a prescription from any telehealth platform, patients should confirm that the signing physician holds an active, unrestricted license in the patient's state.

Pharmacy licensing verification

Winona's dispensing pharmacies must hold active licenses in states where medications are shipped. The National Association of Boards of Pharmacy (NABP) database allows patients to verify pharmacy accreditation. NABP also maintains a "Not Recommended" list of online pharmacies that have violated patient safety standards.

Multi-state prescribing complexity

Telehealth prescribing across state lines involves the prescriber holding a license in the patient's state, not the company's home state. Some states have joined the Interstate Medical Licensure Compact (IMLC), which streamlines multi-state licensing. Patients in states not covered by IMLC compacts should confirm that Winona's physicians are individually licensed in their state before proceeding.

Clinical Evidence Behind Winona's Core Treatments

Winona's clinical rationale rests on the established evidence base for HRT in menopause. The evidence for systemic estrogen in treating vasomotor symptoms is strong.

Vasomotor symptom relief

The REPLENISH trial (N=1,835) demonstrated that a combined 17-beta estradiol/progesterone oral capsule (TX-001HR, now approved as Bijuva) significantly reduced moderate-to-severe hot flashes versus placebo at 12 weeks (P<0.001). The Women's Health Initiative (WHI) Memory Study and the broader WHI (N=161,809 enrolled) remain the most cited long-term safety datasets for systemic HRT, though their applicability to younger, recently menopausal women is debated extensively in the literature.

Cardiovascular timing hypothesis

The 2017 NAMS position statement on HRT and subsequent analyses support the "timing hypothesis": women who initiate HRT within 10 years of menopause onset or before age 60 appear to have a more favorable cardiovascular risk profile than those who initiate HRT later. Winona's intake forms do not replace a physician's ability to apply this nuanced clinical guidance on a case-by-case basis, which is why synchronous follow-up is recommended by multiple guidelines before continuing therapy beyond the initial prescription period.

Bone density data

Estrogen therapy preserves bone mineral density. A Cochrane review (Wells et al., 2002, updated evidence base) found that HRT reduces vertebral and non-vertebral fracture risk in postmenopausal women. Patients who begin HRT through a telehealth platform for symptom relief may gain this secondary benefit, but DEXA scanning to establish baseline bone density is not part of Winona's current intake process.

How Winona Compares to Accredited Alternatives

Several competing telehealth menopause platforms do hold LegitScript certification or work exclusively through NABP-accredited pharmacies. Patients who prioritize verified third-party oversight may want to compare options.

Platforms with LegitScript certification

Hims and Hers Health, Ro Health, and Amazon Clinic have all obtained LegitScript certification for their pharmacy and prescribing operations, which gives them access to paid pharmaceutical advertising channels and provides patients with a baseline verification. This does not mean those platforms are clinically superior to Winona, but it does represent an additional accountability layer.

In-person menopause care

The Menopause Society's "NAMS-Certified Menopause Practitioner" (NCMP) directory lists clinicians who have passed a competency examination in menopause medicine. For patients who have complex risk histories, including prior breast cancer, thrombophilia, or cardiovascular disease, a NCMP-credentialed clinician provides a level of evaluation depth that no asynchronous intake form currently replicates.

Practical Steps Before Using Winona

Patients considering Winona should take five concrete actions before placing an order.

First, look up the dispensing pharmacy's name (disclosed in Winona's terms and at checkout) using the NABP pharmacy verification tool. Second, search the signing physician's name on your state medical board's public license database. Third, ask Winona's support team specifically whether your prescription will be for an FDA-approved product or a compounded formulation, and request a COA if it is compounded. Fourth, review Winona's cancellation policy before entering payment information, and screenshot the cancellation confirmation if you ever cancel. Fifth, schedule a follow-up with a local clinician within 6 months of starting any systemic HRT to review labs and blood pressure.

These steps apply to every cash-pay HRT telehealth company, not just Winona.

Summary of Winona's Regulatory and Accreditation Profile

Winona operates in a legal gray zone that is common to many cash-pay telehealth HRT companies. It is not an illegal operation, but it lacks the third-party verification signals that more established telemedicine platforms carry.

The platform's primary accountability mechanisms are state medical board oversight of its prescribing physicians and state board of pharmacy oversight of its compounding partners. Neither federal accreditation nor LegitScript certification provides an additional verification layer at this time.

Patients with straightforward menopause symptoms, no major comorbidities, and limited access to local menopause-trained clinicians may find Winona a reasonable option, provided they independently verify physician and pharmacy credentials. Patients with complex histories should seek synchronous evaluation with a NCMP-credentialed clinician before beginning or continuing systemic HRT through any telehealth platform.

The FDA's 2023 consumer guidance on HRT and compounded hormones recommends that patients always ask whether a prescribed hormone product is FDA-approved or compounded and review the risks of each category with a qualified prescriber.